BRAINAURORA-B's stock plummeted 9.38% during intraday trading on Thursday, marking a significant downward movement for the session.
The sharp decline represents a pullback and profit-taking activity following a substantial speculative surge earlier in the week, where the stock had rallied as much as 55% on momentum within the brain-computer interface (BCI) sector. The prior rally was triggered by significant industry developments, including the launch of China's first 128-channel fully implantable invasive BCI system clinical trial and announcements from Neuralink regarding planned blindness-treatment implant surgeries.
BrainAurora Medical Technology provides digital therapeutics software solutions for cognitive impairment, serving hospitals and patients with disorders caused by various neurological and psychiatric conditions.
Comments